CN112500374B - Compound tenellone K, preparation method thereof and application thereof in preparing antitumor drugs - Google Patents
Compound tenellone K, preparation method thereof and application thereof in preparing antitumor drugs Download PDFInfo
- Publication number
- CN112500374B CN112500374B CN202011410995.0A CN202011410995A CN112500374B CN 112500374 B CN112500374 B CN 112500374B CN 202011410995 A CN202011410995 A CN 202011410995A CN 112500374 B CN112500374 B CN 112500374B
- Authority
- CN
- China
- Prior art keywords
- compound
- volume ratio
- tenolone
- ethyl acetate
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 63
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 16
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229930191501 Tenellone Natural products 0.000 title claims description 17
- 238000000855 fermentation Methods 0.000 claims abstract description 13
- 230000004151 fermentation Effects 0.000 claims abstract description 13
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 8
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 6
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 6
- 206010018338 Glioma Diseases 0.000 claims abstract description 6
- 201000007270 liver cancer Diseases 0.000 claims abstract description 6
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000001963 growth medium Substances 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 244000061456 Solanum tuberosum Species 0.000 claims description 11
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 11
- 238000010898 silica gel chromatography Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 238000004809 thin layer chromatography Methods 0.000 claims description 9
- 241000209094 Oryza Species 0.000 claims description 8
- 235000007164 Oryza sativa Nutrition 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 235000009566 rice Nutrition 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 235000002639 sodium chloride Nutrition 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 230000014759 maintenance of location Effects 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 6
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 claims description 5
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 238000009630 liquid culture Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000007836 KH2PO4 Substances 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 3
- 238000002953 preparative HPLC Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000011894 semi-preparative HPLC Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002024 ethyl acetate extract Substances 0.000 claims description 2
- 230000001502 supplementing effect Effects 0.000 claims description 2
- 241000461379 Diaporthe lithocarpus Species 0.000 abstract description 12
- 238000012360 testing method Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 3
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000002211 ultraviolet spectrum Methods 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000001026 1H--1H correlation spectroscopy Methods 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001480007 Phomopsis Species 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 125000000830 polyketide group Chemical group 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
- C07D303/26—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds having one or more free hydroxyl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D301/00—Preparation of oxiranes
- C07D301/32—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
Abstract
The invention discloses a compound tenolone K, a preparation method thereof and application thereof in preparing antitumor drugs. The structural formula of the compound tenolone K is shown in a formula (I), and the compound tenolone K is obtained by separating and preparing from a fermentation culture of a marine fungus Phomopsis lithocarpus FS 508. Proved by tests, the compound tenolone K has IC on liver cancer cells HepG-2, breast cancer cells MCF-7, glioma cells SF-268 and non-small cell lung cancer cells A54950The value range is 11.36-51.62 mu M, the anti-tumor activity is relatively obvious, and the anti-tumor drug can be used for preparing anti-tumor drugs.
Description
Technical Field
The invention belongs to the technical field of medical biology, and particularly relates to a marine source compound tenolone K, a preparation method thereof and application thereof in preparing antitumor drugs.
Background
Since the discovery of thymidines (spongothymidines) and uridine (spongouridines) from the sponge Tectithya cryptata of the Caribbean in the 50 s of the last century, marine natural products have become new research hotspots for drug discovery. At present, marine microorganisms become important sources for exploring novel medicaments with novel structures, unique functions and remarkable activities, and have wide development prospects in aspects of innovative medicament exploration, novel enzyme preparation development, development of biological products with special functions, development of health-care products and the like. Phomopsis fungi are capable of producing structurally diverse novel secondary metabolites including various types of natural products such as terpenes, cytokinins, polyketides, steroids, lactones, and enols. Moreover, most of the natural products have wide biological activities such as anti-tumor, anti-inflammatory, antibacterial, antioxidant, antiviral and the like.
Disclosure of Invention
The first purpose of the invention is to provide a marine source compound, tenellone K, with antitumor activity.
The structure of the compound tenolone K is shown as the formula (I):
the second purpose of the invention is to provide a preparation method of a compound tenolone K, wherein the compound tenolone K is separated and prepared from a fermentation culture of a marine fungus Phomopsis lithocarpus FS508, and the preparation method specifically comprises the following steps:
(1) preparing a solid fermentation culture of a marine fungus Phomopsis lithocarpus FS508, extracting the solid fermentation culture by using ethyl acetate, and concentrating an ethyl acetate extract to obtain an extract;
(2) subjecting the extract to silica gel column chromatography, and performing gradient elution with petroleum ether/ethyl acetate at volume ratios of 10:1,5:1,2:1,1:1,0:1 and dichloromethane/methanol at volume ratios of 10:1,5:1 and 0:1 respectively as eluents; the petroleum ether/ethyl acetate fractions eluted at a volume ratio of 5:1 were collected and purified by TLC thin layer chromatography with n-hexane: developing ethyl acetate at a ratio of 1:2v/v to obtain a component Fr.6 with Rf of 0.3-0.4;
fr.6 separating by silica gel column chromatography with n-hexane/ethyl acetatePerforming gradient elution on the ester according to the volume ratio of 5:1,2:1,1:1,1:2, and collecting a component Fr.6-6 eluted by n-hexane/ethyl acetate according to the volume ratio of 2: 1; component Fr.6-6 is subjected to further C-18 reverse phase silica gel column chromatography with MeOH/H2Performing gradient elution on O according to the volume ratio of 70:30 → 100:0 to obtain 7 fractions Fr.6-6-1 to Fr.6-6-7; collect MeOH/H2The component Fr.6-6-3 and Fr.6-6-3 eluted by the volume ratio of 80:20 are separated by Sephadex LH-20 and are separated by CH2Cl2Eluting with MeOH at a volume ratio of 1:1, and combining the same components in the main spot by TLC spot plate to obtain 4 components Fr.6-6-3-1-Fr.6-6-3-4; and further carrying out silica gel column chromatographic separation on a component Fr.6-6-3-3 obtained by using a developing agent n-hexane/ethyl acetate according to the volume ratio of 2:1 and the Rf value of 0.5-0.6, eluting by using n-hexane/ethyl acetate according to the volume ratio of 5:1,2:1,1:1, collecting a component Fr.6-6-3-3-4 eluted by using the n-hexane/ethyl acetate according to the volume ratio of 2:1, and separating and purifying the component Fr.6-6-3-3-4 by using HPLC (high performance liquid chromatography) to obtain a compound tenellone K.
Further, the separation and purification of the component Fr.6-6-3-3-4 by HPLC specifically comprises the following steps: separating by full preparative HPLC on A YMC-pack ODS-A column with A mobile phase of methanol/water in A volume ratio of 80:20 and A flow rate of 6mL/min, collecting the eluted components with A retention time of 12min to obtain A component Fr.6-6-3-3-4-5, subjecting Fr.6-6-3-3-4-5 to further semi-preparative HPLC, using the YMC-pack ODS-A/AQ column with A mobile phase of acetonitrile/water in A volume ratio of 65:35 and A flow rate of 2mL/min, collecting the eluted components with A retention time of 26.2min to obtain the compound tenellone K.
The solid fermentation culture for preparing the marine fungus Phomopsis lithocarpus FS508 comprises the following specific steps: inoculating FS508 hyphae into a potato glucose liquid culture medium, culturing for 5 days at 28 ℃ and 120r/min to prepare a seed solution, then inoculating the seed solution into a rice culture medium according to the inoculation amount of 0.1mL/g, and culturing for 30 days at 28 ℃ to prepare a solid fermentation culture of FS508, wherein each liter of the potato glucose liquid culture medium is prepared by the following method: boiling 200g of potato in 500mL of pure water for 20min, filtering to obtain potato juice, and adding glucose 20g and KH2PO4 3g、MgSO41.5g, vitamin B110mg of waterSupplementing to 1000mL, and sterilizing to obtain the final product; the rice culture medium is prepared by the following method: mixing 250g rice with 300mL of crude sea salt water solution with mass volume ratio of 0.5% g/mL, and sterilizing.
The third purpose of the invention is to provide the application of the compound tenolone K or the medicinal salt thereof in preparing the antitumor drugs. The anti-tumor drug is preferably a drug for resisting liver cancer, breast cancer, glioma or non-small cell lung cancer.
Experiments show that the compound tenolone K has IC (integrated Circuit) on liver cancer cells HepG-2, breast cancer cells MCF-7, glioma cells SF-268 and non-small cell lung cancer cells A54950The value range is 11.36 to 51.62 μ M. IC of positive control cisplatin on four tumor cell lines50The values were 2.13, 3.02, 3.25 and 2.65. mu.M, respectively. This result shows that: the compound tenellone K has relatively obvious antitumor activity.
The fourth purpose of the invention is to provide an antitumor drug, which contains the compound tenolone K or the medicinal salt thereof as an active ingredient, preferably, the antitumor drug is a drug for resisting liver cancer, breast cancer, glioma or non-small cell lung cancer.
The fifth object of the present invention is to provide the use of the marine fungus Phomopsis lithocarpus FS508 for the preparation of the above-mentioned compound tenolone K.
Compared with the prior art, the invention has the advantages that:
the compound tenolone K is separated and prepared from marine fungus Phomopsis lithocarpus FS508, has relatively obvious antitumor activity, can be used for preparing antitumor drugs, provides candidate compounds for researching and developing new antitumor drugs, and provides scientific basis for developing and utilizing natural active substances from marine microorganisms.
The marine fungus Phomopsis lithocarpus FS508 of the present invention was deposited at the Guangdong province culture Collection (GDMCC) at 8.8.15.2018, with the address: no. 59 building 5 of No. 100 Dazhong Ji of Pieli, Guangzhou city, its preservation number is GDMCC No. 60433.
Drawings
FIG. 1 is an HR-ESIMS spectrum of compound tenolone K;
FIG. 2 is a drawing of the compound tenolone K1H NMR spectrum;
FIG. 3 is a drawing of the compound tenolone K13C NMR spectrum;
FIG. 4 is a drawing of the compound tenolone K1H-1H COSY spectrum;
FIG. 5 is the HSQC spectrum of compound tenolone K;
FIG. 6 is an HMBC spectrum of compound tenolone K;
FIG. 7 is a UV spectrum of compound tenolone K;
FIG. 8 is a CD spectrum of compound tenolone K;
FIG. 9 is an IR spectrum of compound tenolone K.
Detailed Description
The following examples are further illustrative of the present invention and are not intended to be limiting thereof.
Example 1
1. Isolation, purification and characterization of the marine fungus Phomopsis lithocarpus FS508
The marine fungus Phomopsis lithocarpus FS508 of the invention is separated from deep sea sediments of Indian ocean (16 degrees 50.508'N,111 degrees 53.335' E, water depth 3606 meters) in 2016 (5 months) in 2016, and is identified by ITS sequence analysis, and GenBank gene accession numbers are: MG686131, identified by blast alignment and homology analysis as belonging to the genus Phomopsis, named Phomopsis lithocarpus FS508, deposited at the guangddong collection of microbial cultures (GDMCC) at 8, 15 months in 2018, address: no. 59 building 5 of No. 100 Dazhong Ji of Pieli, Guangzhou city, its preservation number is GDMCC No. 60433.
2. Solid fermentation of Phomopsis lithocarpus FS508
Inoculating activated mycelium of Phomopsis lithocarpus FS508 to potato glucose liquid culture medium (per liter culture medium is prepared by decocting 200g of potato in 500mL of pure water, boiling for 20min, filtering to obtain potato juice, adding glucose 20g and KH2PO4 3g、MgSO41.5g, vitamin B110mg, made by supplementing to 1000mL with water and sterilizing), cultured at 28 ℃ for 5 days at 120r/min to prepare a seed solution, and then inoculated into a rice medium in an inoculum size of 0.1mL/g (prepared by the following method: mixing 250g rice with 300mL of crude sea salt water solution with mass volume ratio of 0.5% mg/mL, autoclaving at 121 deg.C for 20min, and cooling) and culturing at 28 deg.C for 30 days to obtain FS508 solid fermentation culture.
3. Preparation of compound tenellone K
(1) Adding ethyl acetate into FS508 solid fermentation culture, soaking and extracting for 24 hours, repeatedly extracting for 3 times, mixing the extracting solutions, and concentrating to obtain extract (177.9 g).
(2) Subjecting the extract obtained in the step (1) to silica gel column chromatography, and performing gradient elution by using petroleum ether/ethyl acetate as an eluent in a volume ratio of 10:1,5:1,2:1,1:1,0:1 and dichloromethane/methanol in a volume ratio of 10:1,5:1,0:1 respectively; the petroleum ether/ethyl acetate fractions eluted at a volume ratio of 5:1 were collected and purified by TLC thin layer chromatography with n-hexane: developing ethyl acetate at a ratio of 1:2v/v to obtain a component Fr.6 with Rf of 0.3-0.4;
fr.6 separating by silica gel column chromatography, gradient eluting with n-hexane/ethyl acetate at volume ratio of 5:1,2:1,1:1,1:2, collecting component Fr.6-6 eluted with n-hexane/ethyl acetate at volume ratio of 2: 1; component Fr.6-6 is subjected to further C-18 reverse phase silica gel column chromatography with MeOH/H2Performing gradient elution on O according to the volume ratio of 70:30 → 100:0 to obtain 7 fractions Fr.6-6-1 to Fr.6-6-7; collect MeOH/H2The component Fr.6-6-3 and Fr.6-6-3 eluted by the volume ratio of 80:20 are separated by Sephadex LH-20 and are separated by CH2Cl2Eluting with MeOH at a volume ratio of 1:1, and combining the same components in the main spot by TLC spot plate to obtain 4 components Fr.6-6-3-1-Fr.6-6-3-4; fr.6-6-3-3-3 (a developing agent is n-hexane/ethyl acetate of 2:1v/v, and the Rf value is 0.5-0.6) is further subjected to silica gel column chromatography separation, n-hexane/ethyl acetate is used for elution according to the volume ratio of 5:1,2:1,1:1, and a component Fr.6-6-3-3-4 eluted according to the volume ratio of 2:1 of n-hexane/ethyl acetate is collected;
separating the component Fr.6-6-3-3-4 by full preparative HPLC on A YMC-pack ODS-A column with A mobile phase of methanol/water in A volume ratio of 80:20 and A flow rate of 6mL/min, collecting the eluted component with A retention time of 12min to obtain A component Fr.6-6-3-3-4-5, subjecting Fr.6-6-3-3-4-5 to further semi-preparative HPLC using A YMC-pack ODS-A/AQ column with A mobile phase of acetonitrile/water in A volume ratio of 65:35 and A flow rate of 2mL/min, collecting the eluted component with A retention time of 26.2min to obtain A compound tenellone K (1.1 mg).
4. Structural identification of compound tenolone K
1H-NMR、13C-NMR and HMBC nuclear magnetic resonance spectrograms are measured by a Bruker advanced-600 nuclear magnetic resonance spectrometer, and Tetramethylsilane (TMS) is taken as an internal standard; ESI-MS data were measured with VG Autospec-3000 type mass spectrometer; the ultraviolet spectrum is measured by an Shimadzu UV-2600 spectrophotometer, and the structure identification is as follows:
as shown in FIGS. 1-9, FIG. 1 is an HR-ESIMS spectrum of the compound tenolone K; FIG. 2 is a drawing of the compound tenolone K1H NMR spectrum; FIG. 3 is a drawing of the compound tenolone K13C NMR spectrum; FIG. 4 is a drawing of the compound tenolone K1H-1H COSY spectrum; FIG. 5 is the HSQC spectrum of compound tenolone K; FIG. 6 is an HMBC spectrum of compound tenolone K; FIG. 7 is a UV spectrum of compound tenolone K; FIG. 8 is a CD spectrum of compound tenolone K; FIG. 9 is an IR spectrum of compound tenolone K.
The compound tenellone K was a yellow oil (nuclear magnetic data are shown in table 1); according to HRESIMS [ M + Na ]]+m/z 465.1884，C25H30NaO7Calculated value of 465.1877, the molecular formula of the compound was determined to be C25H30O7Unsaturation is 11;1H-NMR spectrum showed four olefinic proton signals [6.88(d, J ═ 8.3Hz, H-4),7.11(d, J ═ 8.3Hz, H-5),5.05(t, J ═ 97.3Hz, H-18),7.04(s, H-4')](ii) a5 methyl hydrogen signals [ delta ]H 1.64(s,H3-10),1.60(s,H3-11),2.12(s,H3-7'),1.31(s,H3-11'),1.27(s H3-12′)]。13The C-NMR spectrum and the HSQC spectrum showed 25 carbon signals in Compound 1, including 13 quaternary carbons (including 1 carbonyl carbon), 4 methines, 3 methylenes, and 5 methyl groups. Above knotThe compound tenellone K is shown to be a typical tenellone derivative. The structure of the compound tenolone K is determined by further analyzing two-dimensional spectrograms of COSY, HSQC, HMBC and the like.
TABLE 1 Nuclear magnetic data of the compound tenolone K (600MHz/150MHz, delta in ppm, J in Hz)
*Not detected；**Detected by HMBC
The structural formula of the target compound tenolone K separated by the method is shown as the formula (I):
example 2
The anti-tumor activity of compound tenolone K was tested using the SRB method (Skehan P, stopping R, Dominic S.New colorimetric cytoxicity assay for anti-cancer-drug screening [ J ]. J Natl cancer Inst,1990,82: 1107-1112.).
1. Test reagents: the compound tenellone K prepared by the invention is dissolved by dimethyl sulfoxide (DMSO) to obtain a mother solution with the concentration of 10mg/mL, and then the mother solution is diluted to the required concentration by RPMI-1640 culture medium. The positive control is cisplatin aqueous solution.
The tumor cell strains used in the experiment are liver cancer cell HepG-2, breast cancer cell MCF-7, glioma cell SF-268 and non-small cell lung cancer cell A549.
2. The experimental method comprises the following steps: taking HepG-2, MCF-7, SF-268 and A549 cells in logarithmic growth phase, digesting with pancreatin, staining and counting with trypan blue, adjusting the cell concentration to 3 x 10 by using fresh RPMI-1640 culture medium after detecting that the cell activity is more than 95% by using trypan blue exclusion experiment4cell/mL, cell inoculation in96-well plate, adding 180 μ L cell suspension per well, setting 3 blank wells for zero setting, and adjusting temperature at 37 deg.C and 5% CO2The incubator is used for 24 h. After the cells are attached to the wall, 20 mu L of a solution of the compound tenolone K with a certain concentration is added into each hole, 20 mu L of RPMI-1640 culture medium is added into the negative control, and cisplatin is used as the positive control. Placing at 37 ℃ and 5% CO2Culturing in incubator for 72h, adding 50 μ L cold trichloroacetic acid aqueous solution with volume fraction of 50% to fix cells, standing at 4 deg.C for 1h, washing with distilled water for 5 times, and air drying. Sulforhodamine B (SRB) 4mg/mL solution prepared from 1% glacial acetic acid solution by volume fraction was added to 100. mu.L/well, stained at room temperature for 30min, the supernatant was removed, washed 5 times with 1% v/v glacial acetic acid solution, and air-dried. Finally adding 200 mu L/hole of Tris solution with the concentration of 10mmol/mL, measuring the absorbance (A) at 570nm by using a microplate reader, and calculating the inhibition rate of the drug on the cell growth by using the following formula: cell growth inhibition (%) - (1-A)Sample set/AControl group)×100％。
3. The experimental results are as follows: the cytotoxicity of the compound tenolone K prepared by the invention on four tumor cells is shown in Table 2. This result shows that: the compound tenellone K has relatively obvious antitumor activity, so that the compound tenellone K provides candidate compounds for researching and developing new antitumor drugs, and provides scientific basis for developing and utilizing natural active substances derived from deep-sea microorganisms.
TABLE 2 inhibitory Effect of the Compound tenolone K on cancer cells
The above is only a preferred embodiment of the present invention, and it should be noted that the above preferred embodiment should not be considered as limiting the present invention, and the protection scope of the present invention should be subject to the scope defined by the claims. It will be apparent to those skilled in the art that various modifications and adaptations can be made without departing from the spirit and scope of the invention, and these modifications and adaptations should be considered within the scope of the invention.
Claims (6)
1. A compound, tenellone K, represented by the formula (І):
formula (І).
2. A process for the preparation of the compound tenolone K of claim 1 wherein said compound tenolone K is obtained from marine fungiPhomopsis lithocarpusSeparating and preparing the fermentation culture of FS 508; the method specifically comprises the following steps:
(1) preparation of marine fungiPhomopsis lithocarpusExtracting the solid fermentation culture of FS508 by using ethyl acetate, and concentrating an ethyl acetate extract to obtain an extract;
(2) subjecting the extract to silica gel column chromatography, and performing gradient elution with petroleum ether/ethyl acetate at volume ratios of 10:1,5:1,2:1,1:1,0:1 and dichloromethane/methanol at volume ratios of 10:1,5:1 and 0:1 respectively as eluents; the petroleum ether/ethyl acetate fractions eluted at a volume ratio of 5:1 were collected and purified by TLC thin layer chromatography with n-hexane: ethyl acetate =1: 2v/v developing a component fr.6 with Rf = 0.3-0.4;
fr.6 separating by silica gel column chromatography, gradient eluting with n-hexane/ethyl acetate at volume ratio of 5:1,2:1,1:1,1:2, collecting component Fr.6-6 eluted with n-hexane/ethyl acetate at volume ratio of 2: 1; component Fr.6-6 is subjected to further C-18 reverse phase silica gel column chromatography with MeOH/H2Performing gradient elution on O according to the volume ratio of 70:30 → 100:0 to obtain 7 fractions Fr.6-6-1 to Fr.6-6-7; collect MeOH/H2The component Fr.6-6-3 and Fr.6-6-3 eluted by the volume ratio of 80:20 are separated by Sephadex LH-20 and are separated by CH2Cl2The MeOH eluted at a volume ratio of 1:1 was combined by TLC spot platesThe same components are spotted to obtain 4 components Fr.6-6-3-1 to Fr.6-6-3-4; further separating a component Fr.6-6-3-3 with a developing agent of n-hexane/ethyl acetate according to a volume ratio of 2:1 and an Rf value of 0.5-0.6 by silica gel column chromatography, eluting with n-hexane/ethyl acetate according to a volume ratio of 5:1,2:1,1:1, collecting a component Fr.6-6-3-4 eluted by the n-hexane/ethyl acetate according to a volume ratio of 2:1, and separating and purifying the component Fr.6-6-3-3-4 by HPLC to obtain a compound tenellone K;
the separation and purification of the component Fr.6-6-3-3-4 by HPLC specifically comprises the following steps: separating by full preparative HPLC on A YMC-pack ODS-A column with A mobile phase of methanol/water in A volume ratio of 80:20 and A flow rate of 6mL/min, collecting the eluted components with A retention time of 12min to obtain A component Fr.6-6-3-3-4-5, subjecting Fr.6-6-3-3-4-5 to further semi-preparative HPLC, using the YMC-pack ODS-A/AQ column with A mobile phase of acetonitrile/water in A volume ratio of 65:35 and A flow rate of 2mL/min, collecting the eluted components with A retention time of 26.2min to obtain the compound tenellone K.
3. The method according to claim 2, wherein the step (1) of preparing marine fungiPhomopsis lithocarpusThe solid fermentation culture of FS508 comprises the following specific steps: inoculating FS508 hyphae into a potato glucose liquid culture medium, culturing for 5 days at 28 ℃ and 120r/min to prepare a seed solution, then inoculating the seed solution into a rice culture medium according to the inoculation amount of 0.1mL/g, and culturing for 30 days at 28 ℃ to prepare a solid fermentation culture of FS508, wherein each liter of the potato glucose liquid culture medium is prepared by the following method: boiling 200g of potato in 500mL of pure water for 20min, filtering to obtain potato juice, and adding glucose 20g and KH2PO4 3 g、MgSO41.5g, vitamin B110mg, supplementing water to 1000mL, and sterilizing; the rice culture medium is prepared by the following method: mixing 250g rice with 300mL of crude sea salt water solution with mass volume ratio of 0.5% g/mL, and sterilizing.
4. The use of the compound tenolone K or pharmaceutically acceptable salt thereof of claim 1 for the preparation of an antitumor medicament; the anti-tumor drug is a drug for resisting liver cancer, breast cancer, glioma or non-small cell lung cancer.
5. An antitumor agent characterized by comprising the compound tenolone K according to claim 1, or a pharmaceutically acceptable salt thereof as an active ingredient.
6. Marine fungiPhomopsis lithocarpusUse of FS508 for the preparation of the compound tenolone K according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011410995.0A CN112500374B (en) | 2020-12-03 | 2020-12-03 | Compound tenellone K, preparation method thereof and application thereof in preparing antitumor drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011410995.0A CN112500374B (en) | 2020-12-03 | 2020-12-03 | Compound tenellone K, preparation method thereof and application thereof in preparing antitumor drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112500374A CN112500374A (en) | 2021-03-16 |
| CN112500374B true CN112500374B (en) | 2022-04-15 |
Family
ID=74971845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011410995.0A Active CN112500374B (en) | 2020-12-03 | 2020-12-03 | Compound tenellone K, preparation method thereof and application thereof in preparing antitumor drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112500374B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3088396A1 (en) * | 2015-04-30 | 2016-11-02 | FUNDACIÓN MEDINA. Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía | Phenol derivatives to treat cancer |
| CN110642827B (en) * | 2019-09-09 | 2022-08-30 | 广东省微生物研究所（广东省微生物分析检测中心） | Compounds of photosteroids A and B, preparation method thereof and application thereof in preparing antitumor drugs |
-
2020
- 2020-12-03 CN CN202011410995.0A patent/CN112500374B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN112500374A (en) | 2021-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112592350B (en) | Polyketide lithocarpin E-G and preparation method and application thereof | |
| CN109336873B (en) | Compound lithocarolsA-F, preparation method thereof and application thereof in preparation of antitumor drugs | |
| CN109232513B (en) | Compound litocarpinols, preparation method thereof and application thereof in preparation of antitumor drugs | |
| CN110642827B (en) | Compounds of photosteroids A and B, preparation method thereof and application thereof in preparing antitumor drugs | |
| CN111285758B (en) | Preparation method of compound trieffulsols C-E and application of compound trieffulsols C-E in preparation of anti-inflammatory drugs | |
| CN111004251B (en) | Marine-derived heteroterpene compounds I and II, preparation method and application thereof in preparation of antitumor drugs | |
| CN108570025B (en) | Oxygen-containing five-membered ring pimarane diterpenoid compound, preparation method and application thereof | |
| CN109776561B (en) | Compounds Cytorhizins B and C, preparation method thereof and application thereof in preparation of antitumor drugs | |
| CN111808088B (en) | Compounds tersaphilone B and E, preparation method thereof and application thereof in preparing antitumor drugs | |
| CN112500374B (en) | Compound tenellone K, preparation method thereof and application thereof in preparing antitumor drugs | |
| CN107501072B (en) | Compound colletotriconeA, preparation method thereof and application thereof in preparing antitumor drugs | |
| CN102746995B (en) | Preparation method for isochromophilone VIII and application of same in preparation of antineoplastic drugs | |
| CN107739361A (en) | Come from aspergillus versicolor anthraquinone analog compound and prepare the application of anti-human colon cancer drug | |
| CN111471050B (en) | Staurosporine derivatives and preparation method and application thereof | |
| CN107739362A (en) | Come from aspergillus versicolor anthraquinone analog compound and prepare the application of anti-human oesophagus cancer drug | |
| CN1683374A (en) | Indole carbazole alkaloid and its preparing method and use | |
| CN112300188B (en) | Compounds myrothecin H and I, and preparation method and application thereof | |
| CN114213428B (en) | Indole alkaloid compound and preparation method and application thereof | |
| CN112125918A (en) | Aromatic polyketone compounds Talarogyoxanones A and B as well as preparation method and application thereof | |
| CN114891017B (en) | Maleic anhydride alicyclic compound and preparation method and application thereof | |
| Zhou et al. | Components in antineoplastic actinomycete strain (N2010–37) of bottom mud in mangrove | |
| CN115650854B (en) | Integrin derivative, its preparation method and application in alpha-glucosidase inhibiting medicine | |
| CN114605430B (en) | Macrocyclic dilactone compound, and preparation method and application thereof | |
| CN111205308B (en) | Sulfo-diketone piperazine compound and preparation method and application thereof | |
| CN111606796B (en) | Preparation method of two kinds of oxytetracycline ketone compounds and application of oxytetracycline ketone compounds as antitumor drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 510070 No.56 courtyard, No.100 Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province Patentee after: Institute of Microbiology, Guangdong Academy of Sciences Address before: 510070 No.56 courtyard, No.100 Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province Patentee before: GUANGDONG INSTITUTE OF MICROBIOLOGY (GUANGDONG DETECTION CENTER OF MICROBIOLOGY) |